Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
    • Forum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Publisher Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Publisher Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
    • Forum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleAccepted Article

Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis

Jean W. Liew and Gregory C. Gardner
The Journal of Rheumatology January 2019, jrheum.181018; DOI: https://doi.org/10.3899/jrheum.181018
Jean W. Liew
From the Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington. Address correspondence to Jean W. Liew, MD, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195. Email: jwliew@uw.edu.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory C. Gardner
From the Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington. Address correspondence to Jean W. Liew, MD, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195. Email: jwliew@uw.edu.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective In this retrospective observational study, we assess the efficacy and safety of the interleukin-1 receptor antagonist anakinra in medically complex, hospitalized patients with acute gout and calcium pyrophosphate crystal arthritis.

Methods Adult inpatients patients treated with anakinra from 2014-2017 were identified for inclusion. Charts were reviewed for demographics, comorbidities, laboratory data, pain scores, joint involvement, prior treatment, dosing and response to anakinra, concurrent infections, and surgical interventions. Response to anakinra treatment was determined from review of provider documentation, as well as recorded pain scores on a numeric scale.

Results We identified 100 individuals accounting for 115 episodes of arthritis. This population was 82% male, with an average age of 60 years. Comorbidities included renal disease (45%) and history of organ transplantation (14%). Twenty-nine episodes of arthritis occurred in the perioperative setting. Concurrent infection was present in 34 episodes. Eighty-four episodes of arthritis had partial or complete response to anakinra within four days of treatment initiation; 66 episodes had partial or complete response within one day of anakinra administration. Anakinra was well-tolerated.

Conclusion This is the largest observational study of anakinra use in the inpatient setting for the acute treatment of crystal-associated arthritis. We observed a rapid response to anakinra, with 75% of episodes significantly improving or completely resolving within four days of the first dose. Our data also support the use of this biologic agent in individuals with infections, as well as perioperative individuals and immunosuppressed transplant recipients.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology: 46 (2)
The Journal of Rheumatology
Vol. 46, Issue 2
1 Feb 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
Accepted manuscript
Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis
Jean W. Liew, Gregory C. Gardner
The Journal of Rheumatology Jan 2019, jrheum.181018; DOI: 10.3899/jrheum.181018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis
Jean W. Liew, Gregory C. Gardner
The Journal of Rheumatology Jan 2019, jrheum.181018; DOI: 10.3899/jrheum.181018
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Towards a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group
  • Peritenon extensor tendon inflammation in Psoriatic Arthritis is an enthesitis-related lesion
  • OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions
Show more Accepted Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • AV Rheum
  • Forum

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Company Limited
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire